It has been previously reported that mutations of TPI carrying the tyrosine substitutions Y165F and Y209F, both of which are located at the catalytic center, render this enzyme inefficient when expressed in human neuroblastoma cells thereby shifting the balance between GAP and DHAP toward the latter and reducing cell viability (23). Here, TPI1 is linked to neuroblastoma.